Phase II trial of thio-TEPA in relapsed and refractory ovarian carcinoma
| Autor: | Robert B. Catalano, W.Michael Hogan, Peter J. O'Dwyer, Robert L. Comis, Corey J. Langer, Sherry Nash, Norman G. Rosenblum |
|---|---|
| Rok vydání: | 1991 |
| Předmět: |
Adult
medicine.medical_specialty medicine.medical_treatment Phases of clinical research Ovary ThioTEPA Adenocarcinoma Gastroenterology Ovarian carcinoma Internal medicine medicine Carcinoma Humans Aged Ovarian Neoplasms Chemotherapy business.industry Obstetrics and Gynecology Middle Aged medicine.disease Thrombocytopenia Surgery Regimen medicine.anatomical_structure Oncology Carcinoma Squamous Cell Drug Evaluation Female Ovarian cancer business Thiotepa Agranulocytosis medicine.drug |
| Zdroj: | Gynecologic Oncology. 43:242-246 |
| ISSN: | 0090-8258 |
| DOI: | 10.1016/0090-8258(91)90028-4 |
| Popis: | On the basis of a Phase I reevaluation of thio-TEPA in which 3 of 9 patients with ovarian carcinoma responded, we instituted a Phase II study at high doses. Fourteen patients with a histologic diagnosis of epithelial carcinoma of the ovary, who had received at least one prior cisplatin-based regimen, were entered. Thio-TEPA was initially administered intravenously at a dose of 65 mg/m2 every 4 weeks, but was reduced to 50 mg/m2 after severe myelotoxicity developed in the first 5 patients. In 4 patients stable disease lasted 3, 4, 5, and 9 months; 10 patients progressed. There were no objective responses. At this dose and schedule, thio-TEPA has a response rate less than 20% in ovarian cancer patients previously treated with cisplatin. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|